Associate Director, CMC Regulatory
Revolution Medicines
Summary
As part of our expanding organization, we seek a strategic and hands-on Associate Director, CMC Regulatory who will be responsible for executing CMC regulatory strategies to support clinical development, marketing authorizations, and lifecycle management of RevMed’s pipeline compounds/products.
Job description
The Opportunity
As part of our expanding organization, we seek a strategic and hands-on Associate Director, CMC Regulatory who will be responsible for executing CMC regulatory strategies to support clinical development, marketing authorizations, and lifecycle management of RevMed’s pipeline compounds/products.
This role involves coordinating and preparing CMC sections of regulatory submissions to support RevMed’s global clinical trials, market applications and post approval changes. The ideal candidate should have a strong understanding of global regulatory requirements during different phases of development, and be able to provide regulatory guidance to the CMC teams accordingly.
Responsibilities
- Develop, lead, and implement global CMC regulatory strategies to support the clinical development, registration, and post-marketing activities.
- Lead the preparation and maintenance of the CMC / quality sections for regulatory submissions including initial submission of IND, IMPD/CTA, NDA, MAA and amendments to Health Authorities (HAs), and preparation of responses to queries from HAs.
- Serve as the CMC regulatory representative on project teams and provide CMC regulatory support for the development of the investigational product(s) and marketed products and ensure applicable regulatory requirements are appropriately met.
- Collaborate with corporate regulatory team, CMC SMEs and/or CROs to identify regional/country-specific CMC requirements to support global applications, and to drive the CMC submission timelines in order to meet business objectives.
- Provide regulatory assessment and guidance on CMC related change controls, deviations, and investigations throughout product life cycle.
- Lead and/or contribute to internal process improvements, SOP development, and organizational initiatives to support globalization of RevMed’s products. Maintain knowledge of global competitive landscape, regulatory environment, regulations and CMC guidance, providing interpretation to internal stakeholders.
Required Skills, Experience, and Education
- BA/BS degree in Pharmaceutical Science, Chemistry, Chemical Engineering, or closely related field.
- 10+ years of pharmaceutical / biotech drug development experience with 5+ years of experience of global CMC regulatory affairs.
- Experience in CMC related global submissions (IND, IMPD/CTA, NDA, MAA, etc.) (US, EU, APAC, LATAM).
- Solid knowledge of US and international GMP quality regulations, current industry practices, and experience with interpretation and application to development projects and marketed product regulatory issues.
- Working experience and content knowledge in CMC development of NCEs (small molecules) or equivalent.
- Demonstrated experience in effective collaboration with internal and external stakeholders.
- Ability to prioritize and manage multiple projects simultaneously in a dynamic company environment.
- Ability to operate effectively in a fast-paced, matrixed, global environment.
- Effective written and verbal communication skills and excellent interpersonal skills.
Preferred Skills
- Advanced degree (MSc or PhD degree) in Pharmaceutical Science, Chemistry, Chemical Engineering, or closely related field is desirable.
- Experience in accelerated development program.
- Self-driven, proactive, and able to operate independently while fostering collaboration across departments.
Requirements
- BA/BS degree in Pharmaceutical Science, Chemistry, Chemical Engineering, or closely related field.
- 10+ years of pharmaceutical / biotech drug development experience with 5+ years of experience of global CMC regulatory affairs.
- Experience in CMC related global submissions (IND, IMPD/CTA, NDA, MAA, etc.) (US, EU, APAC, LATAM).
- Solid knowledge of US and international GMP quality regulations, current industry practices, and experience with interpretation and application to development projects and marketed product regulatory issues.
- Working experience and content knowledge in CMC development of NCEs (small molecules) or equivalent.
- Demonstrated experience in effective collaboration with internal and external stakeholders.
- Ability to prioritize and manage multiple projects simultaneously in a dynamic company environment.
- Ability to operate effectively in a fast-paced, matrixed, global environment.
- Effective written and verbal communication skills and excellent interpersonal skills.
- Advanced degree (MSc or PhD degree) in Pharmaceutical Science, Chemistry, Chemical Engineering, or closely related field is desirable.
- Experience in accelerated development program.
- Self-driven, proactive, and able to operate independently while fostering collaboration across departments.
Benefits
- Competitive cash compensation
- Equity awards
- Learning and development opportunities
Company overview
Revolution Medicines is a clinical-stage precision oncology company focused on developing novel targeted therapies for RAS-addicted cancers. The company is pioneering a new class of therapeutics that target oncogenic RAS mutations, which are among the most common drivers of human cancers. Revolution Medicines employs a unique approach to drug discovery, leveraging deep insights into RAS biology to develop small molecule inhibitors that can address previously undruggable targets. Their pipeline includes multiple clinical-stage candidates designed to inhibit various RAS pathway mutations, with a particular focus on KRAS G12C and other RAS variants. The company's scientific platform combines structural biology, medicinal chemistry, and computational approaches to design highly selective inhibitors. Revolution Medicines aims to transform cancer treatment by developing therapies that can overcome resistance mechanisms and provide durable clinical benefits for patients with RAS-driven malignancies. Their research represents a significant advancement in the field of targeted cancer therapy, addressing one of the most challenging areas in oncology drug development.